BrightGene Bio Medical Technology C (688166) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BrightGene Bio Medical Technology C (688166) has a cash flow conversion efficiency ratio of 0.011x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥26.70 Million ≈ $3.91 Million USD) by net assets (CN¥2.35 Billion ≈ $344.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688166 net asset quality index to measure how much of total assets are equity-financed.
BrightGene Bio Medical Technology C - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how BrightGene Bio Medical Technology C's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of BrightGene Bio Medical Technology C to evaluate the quality of earnings relative to operating cash generation.
BrightGene Bio Medical Technology C Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BrightGene Bio Medical Technology C ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trust Alliance Information Development Inc Ltd Shanghai
SHE:300469
|
-0.039x |
|
Suzhou Hengmingda Electronic Technology Co Ltd
SHE:002947
|
0.040x |
|
Chang Wah Technology Co Ltd
TWO:6548
|
0.038x |
|
Zhejiang XinAn Chemical Industrial Group Co Ltd
SHG:600596
|
0.018x |
|
Hawaiian Electric Industries Inc
NYSE:HE
|
0.037x |
|
CPI Europe AG
VI:CPI
|
0.027x |
|
Empresas Cablevisión S.A.B. de C.V
MX:CABLECPO
|
0.180x |
|
momo.com Inc
TW:8454
|
0.128x |
Annual Cash Flow Conversion Efficiency for BrightGene Bio Medical Technology C (2016–2024)
The table below shows the annual cash flow conversion efficiency of BrightGene Bio Medical Technology C from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see BrightGene Bio Medical Technology C stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.44 Billion ≈ $356.66 Million |
CN¥245.56 Million ≈ $35.93 Million |
0.101x | +25.06% |
| 2023-12-31 | CN¥2.42 Billion ≈ $353.77 Million |
CN¥194.77 Million ≈ $28.50 Million |
0.081x | -41.98% |
| 2022-12-31 | CN¥2.24 Billion ≈ $328.03 Million |
CN¥311.26 Million ≈ $45.55 Million |
0.139x | +37.34% |
| 2021-12-31 | CN¥1.74 Billion ≈ $254.86 Million |
CN¥176.08 Million ≈ $25.77 Million |
0.101x | -6.82% |
| 2020-12-31 | CN¥1.43 Billion ≈ $209.63 Million |
CN¥155.43 Million ≈ $22.74 Million |
0.108x | +132.28% |
| 2019-12-31 | CN¥1.31 Billion ≈ $192.15 Million |
CN¥61.33 Million ≈ $8.98 Million |
0.047x | -43.58% |
| 2018-12-31 | CN¥772.85 Million ≈ $113.09 Million |
CN¥63.99 Million ≈ $9.36 Million |
0.083x | +3.25% |
| 2017-12-31 | CN¥446.02 Million ≈ $65.27 Million |
CN¥35.77 Million ≈ $5.23 Million |
0.080x | -40.63% |
| 2016-12-31 | CN¥220.15 Million ≈ $32.21 Million |
CN¥29.73 Million ≈ $4.35 Million |
0.135x | -- |
About BrightGene Bio Medical Technology C
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also pr… Read more